Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080966 | 0.74 | SCN5A (0.42) | SCN5ADYRK1AMAPTPIK3CDCASP1 | |
| SCHEMBL3089077 | 0.74 | SCN5A (0.42) | SCN5ADYRK1APIK3CDCYP11B1CYP11B2 | |
| SCHEMBL3076621 | 0.74 | SCN5A (0.42) | SCN5ADYRK1APIK3CDESR1RIPK1 | |
| SCHEMBL3077299 | 0.74 | SCN5A (0.42) | SCN5ADYRK1APIK3CDCYP11B1CYP11B2 | |
| SCHEMBL12489513 | 0.74 | SCN5A (0.42) | SCN5ADYRK1AMAPTPIK3CDSMN1; SMN2 | |
| SCHEMBL24449040 | 0.74 | SCN5A (0.42) | SCN5ADYRK1APIK3CDESR1RIPK1 | |
| SCHEMBL4225417 | 0.74 | SCN5A (0.46) | SCN5ADYRK1AMAPTPIK3CDCYP11B1 | |
| SCHEMBL26697694 | 0.72 | SCN5A (0.36) | SCN5AMAPTPIK3CDKDM4ELMNA | |
| SCHEMBL30770141 | 0.72 | SCN5A (0.36) | SCN5AMAPTPIK3CDKDM4ELMNA | |
| SCHEMBL3484150 | 0.72 | DRD2 (0.38) | SCN5AMAPTCYP3A4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025085652-A1 | INDOLE CARBOXAMIDES USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025057074-A1 | N-ARYL BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| CN-119462647-A | Aromatic condensed ring compound, pharmaceutical composition containing aromatic condensed ring compound and application of aromatic condensed ring compound | 杭州禹泓医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025016439-A1 | COMPOUND USED AS CDK2/4 PROTEIN KINASE INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-3947378-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2024-11-13 | — | — | EP | disclosed |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-28 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| WO-2015063093-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014074657-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074657-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | PAH, BCKDK, PKM | SCN5A 491/4885DYRK1A 1030/4885MAPT 2208/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | SCN5A 2888/4885DYRK1A 854/4885MAPT 2560/4885 |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, PDGFRB | SCN5A 2463/4885DYRK1A 3369/4885MAPT 4593/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | SCN5A 1284/4885DYRK1A 4389/4885MAPT 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.